Signal active
Bio
Mike is a General Partner of Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Palo Alto, CA office, where he also serves as a General Partner and Team Leader for Lightstone Ventures.
His representative investments include Altura Medical, Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), GluMetrics, Holaira, MicroVention (acquired by Terumo), NeuroVista, Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome, and TranS1 (NASDAQ: TSON).
Featured on the Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences.
He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program.
Location
Menlo Park, California, United States, North America
Social
N/A
Primary Organization
2012
66
18
12
11-50
Financial Services, Venture Capital, Finance, Health Care, Precision Medicine
Jobs history
1
Allay Therapeutics
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Mike Carusi is the Managing General Partner at Lightstone Ventures, based in United States, North America. With a background in Financial Services, Mike Carusi has a rich history of leadership and innovation. Mike Carusi studied BS unknown @ Lehigh University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
7
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Dec 01, 2015 | EndoGastric Solutions | Venture Round - EndoGastric Solutions | Advanced Technology Ventures | 50.0M |
Apr 13, 2016 | Second Genome | Series B - Second Genome | Advanced Technology Ventures | 51.0M |
Jun 19, 2018 | EndoGastric Solutions | Series I - EndoGastric Solutions | Advanced Technology Ventures | 40.6M |
Feb 11, 2019 | Nuvaira | Series E - Nuvaira | Advanced Technology Ventures | 79.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.